Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications

E. Sticova, M. Jirsa, J. Pawłowska,

. 2018 ; 2018 (-) : 2313675. [pub] 20180726

Jazyk angličtina Země Egypt

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012433

Cholestasis is characterised by impaired bile secretion and accumulation of bile salts in the organism. Hereditary cholestasis is a heterogeneous group of rare autosomal recessive liver disorders, which are characterised by intrahepatic cholestasis, pruritus, and jaundice and caused by defects in genes related to the secretion and transport of bile salts and lipids. Phenotypic manifestation is highly variable, ranging from progressive familial intrahepatic cholestasis (PFIC)-with onset in early infancy and progression to end-stage liver disease-to a milder intermittent mostly nonprogressive form known as benign recurrent intrahepatic cholestasis (BRIC). Cases have been reported of initially benign episodic cholestasis that subsequently transitions to a persistent progressive form of the disease. Therefore, BRIC and PFIC seem to represent two extremes of a continuous spectrum of phenotypes that comprise one disease. Thus far, five representatives of PFIC (named PFIC1-5) caused by pathogenic mutations present in both alleles of ATP8B1, ABCB11, ABCB4, TJP2, and NR1H4 have been described. In addition to familial intrahepatic cholestasis, partial defects in ATP8B1, ABCB11, and ABCB4 predispose patients to drug-induced cholestasis and intrahepatic cholestasis in pregnancy. This review summarises the current knowledge of the clinical manifestations, genetics, and molecular mechanisms of these diseases and briefly outlines the therapeutic options, both conservative and invasive, with an outlook for future personalised therapeutic strategies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012433
003      
CZ-PrNML
005      
20190425114836.0
007      
ta
008      
190405s2018 ua f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2018/2313675 $2 doi
035    __
$a (PubMed)30148122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ua
100    1_
$a Sticova, Eva $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague 4, 140 21, Czech Republic. Department of Pathology, Third Faculty of Medicine, Charles University, Prague 10, 100 00, Czech Republic.
245    10
$a New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications / $c E. Sticova, M. Jirsa, J. Pawłowska,
520    9_
$a Cholestasis is characterised by impaired bile secretion and accumulation of bile salts in the organism. Hereditary cholestasis is a heterogeneous group of rare autosomal recessive liver disorders, which are characterised by intrahepatic cholestasis, pruritus, and jaundice and caused by defects in genes related to the secretion and transport of bile salts and lipids. Phenotypic manifestation is highly variable, ranging from progressive familial intrahepatic cholestasis (PFIC)-with onset in early infancy and progression to end-stage liver disease-to a milder intermittent mostly nonprogressive form known as benign recurrent intrahepatic cholestasis (BRIC). Cases have been reported of initially benign episodic cholestasis that subsequently transitions to a persistent progressive form of the disease. Therefore, BRIC and PFIC seem to represent two extremes of a continuous spectrum of phenotypes that comprise one disease. Thus far, five representatives of PFIC (named PFIC1-5) caused by pathogenic mutations present in both alleles of ATP8B1, ABCB11, ABCB4, TJP2, and NR1H4 have been described. In addition to familial intrahepatic cholestasis, partial defects in ATP8B1, ABCB11, and ABCB4 predispose patients to drug-induced cholestasis and intrahepatic cholestasis in pregnancy. This review summarises the current knowledge of the clinical manifestations, genetics, and molecular mechanisms of these diseases and briefly outlines the therapeutic options, both conservative and invasive, with an outlook for future personalised therapeutic strategies.
650    _2
$a P-glykoproteiny $x nedostatek $x genetika $7 D018435
650    _2
$a ABC transportér, podrodina B, člen 11 $x genetika $7 D000074020
650    _2
$a adenosintrifosfatasy $x genetika $7 D000251
650    _2
$a proteiny přenášející anionty $x metabolismus $7 D027321
650    _2
$a žlučové kyseliny a soli $x biosyntéza $7 D001647
650    _2
$a intrahepatální cholestáza $x genetika $x metabolismus $7 D002780
650    _2
$a lidé $7 D006801
650    _2
$a komplikace těhotenství $x genetika $7 D011248
650    _2
$a receptory cytoplazmatické a nukleární $x genetika $x metabolismus $7 D018160
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Jirsa, Milan $u Laboratory of Experimental Hepatology, Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague 4, 140 21, Czech Republic.
700    1_
$a Pawłowska, Joanna $u Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute (CMHI), Warsaw 04-730, Poland.
773    0_
$w MED00198695 $t Canadian journal of gastroenterology & hepatology $x 2291-2797 $g Roč. 2018, č. - (2018), s. 2313675
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30148122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190425114911 $b ABA008
999    __
$a ok $b bmc $g 1391743 $s 1050738
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 2018 $c - $d 2313675 $e 20180726 $i 2291-2797 $m Canadian journal of gastroenterology & hepatology $n Can J Gastroenterol Hepatol $x MED00198695
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...